P 1Alternative Names: PSE 222; Zemaphyte
Latest Information Update: 19 Nov 1999
At a glance
- Originator Nonindustrial source; Phytopharm
- Developer IXICO
- Mechanism of Action Interleukin 4 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Atopic dermatitis
Most Recent Events
- 19 Nov 1999 P 1 is available for licensing (http://www.phytopharm.co.uk)
- 19 Nov 1999 Suspended-Preclinical for Atopic dermatitis in USA (PO)
- 19 Nov 1999 Suspended-III for Atopic dermatitis in United Kingdom (PO)